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Introduction: Intravenous (IV) injection of mesenchymal stem cells (MSCs) is used to treat systemic human diseases
and disorders but is not routinely used in equine therapy. In horses, MSCs are isolated primarily from adipose tissue
(AT) or bone marrow (BM) and used for treatment of orthopedic injuries through one or more local injections. The
objective of this study was to determine the safety and lymphocyte response to multiple allogeneic IV injections of
either AT-derived MSCs (AT-MSCs) or BM-derived MSCs (BM-MSCs) to healthy horses.
Methods: We injected three doses of 25 × 106 allogeneic MSCs from either AT or BM (a total of 75 × 106 MSCs per
horse) into five and five, respectively, healthy horses. Horses were followed up for 35 days after the first MSC
infusion. We evaluated host inflammatory and immune response, including total leukocyte numbers, serum
cytokine concentration, and splenic lymphocyte subsets.
Results: Repeated injection of allogeneic AT-MSCs or BM-MSCs did not elicit any clinical adverse effects. Repeated
BM-MSC injection resulted in increased blood CD8+ T-cell numbers. Multiple BM-MSC injections also increased
splenic regulatory T cell numbers compared with AT-MSC-injected horses but not controls.
Conclusions: These data demonstrate that multiple IV injections of allogeneic MSCs are well tolerated by healthy
horses. No clinical signs or clinico-pathologic measurements of organ toxicity or systemic inflammatory response
were recorded. Increased numbers of circulating CD8+ T cells after multiple IV injections of allogeneic BM-MSCs
may indicate a mild allo-antigen-directed cytotoxic response. Safety and efficacy of allogeneic MSC IV infusions in
sick horses remain to be determined.Introduction
Mesenchymal stem cells (MSCs) have been isolated from
humans and most veterinary and laboratory animal spe-
cies, including horses [1,2]. In horses, MSCs have primar-
ily been isolated and characterized from adipose tissue
(AT), bone marrow (BM), umbilical cord blood, and um-
bilical cord tissue [3]. The ideal MSC dose for any medical
application has not been determined. Autologous and* Correspondence: dlborjesson@ucdavis.edu
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rently used in clinical applications for tissue regeneration
and repair as well as immunomodulation [3,4].
Allogeneic MSCs offer considerable advantages over
autologous MSCs as they do not require patient-specific
tissue harvest, they are available for immediate applica-
tion, and cell batches can be well characterized, provid-
ing a consistent source of multiple cell doses [5]. In
addition to MSC tissue source, the route of MSC admin-
istration is an important consideration for therapeutic
applications. Equine autologous and allogeneic MSCs
have been safely administered by regional and local in-
jection routes [5-7]. In human clinical trials, intravenouss is an Open Access article distributed under the terms of the Creative
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for systemic MSC administration and permits therapeutic
application to patients with systemic inflammatory or
immune-mediated diseases (cardiovascular disease, re-
spiratory disease, and gastrointestinal disease) [8-10]. Al-
though the IV administration of MSCs to treat horses has
not yet been evaluated, IV injection may be increasingly
used in equine medicine as we move toward cell-based
therapy for systemic inflammatory diseases such as re-
spiratory or gastrointestinal diseases. However, MSCs may
be recognized as foreign by the immune system and this
can result in a systemic inflammatory response directed at
the cells or, at the very least, immune destruction of these
cells with a resultant decrease in MSC life span and effi-
cacy. A safety study demonstrated that a single dosage of
0.2 to 1 × 106 IV allogeneic MSCs in 291 horses was not
associated with any clinical adverse effects [11]. This study
demonstrated the safety of IV allogeneic MSC administra-
tion in a large cohort of healthy horses. In our study, we
administered three MSC doses that are 25- to 125-fold
higher than what was previously reported. Moreover, only
a single tissue source (peripheral blood) of MSCs was used
and only clinical outcomes were recorded [11].
Multiple MSC injections may be therapeutically ad-
vantageous for orthopedic and immunomodulatory con-
ditions [4]. The current standard of care in human
patients often involves multiple injections, frequently by
different routes of administration (for example, a local
injection followed by a regional injection). Safety after
multiple local MSC injections in horses has largely been
demonstrated [5,7]; however, there is limited detailed in-
formation on the safety of repeated IV allogeneic MSC
injections in horses [5,11].
MSCs modulate anti-inflammatory cytokine secretion
and leukocyte phenotype ratios both in vitro and in vivo.
In vitro, MSCs inhibit T- and B-cell proliferation in both
humans and horses [1,12]. In humans, MSCs secrete
T cell-modulating factors, including prostaglandin E2
(PGE2), and control regulatory T (Treg) cell function
[13,14]. Equine MSCs inhibit inflammatory mediator
production—that is, interferon-gamma (IFN-γ) and tumor
necrosis factor-alpha (TNF-α)—while upregulating the pro-
duction of T cell-modulating and anti-inflammatory cell
mediators (that is, transforming growth factor-beta (TGF-β)
and PGE2) [3,15]. Recently, equine MCSs were reported
to have variable major histocompatibility complex II
(MHC-II) expression, which was correlated with induction
of T-cell proliferation in vitro [16]. In vivo, MSCs
modulate CD4+ and CD8+ T-cell numbers [10,17]. It is
unknown whether systemically administered equine
MSCs alter inflammatory cytokine levels, leukocyte
numbers, or Treg cell numbers in vivo.
The objective of this study was to test the safety of mul-
tiple, allogeneic IV MSC doses in horses. We hypothesizedthat repeated IV MSC administration from either AT or
BM would not elicit a systemic inflammatory immune
response. We further hypothesized that IV MSC adminis-
tration would result in increased Treg cell numbers. To
test these hypotheses, we measured blood and splenic
leukocyte numbers and subsets and systemic serum cyto-
kine concentrations over the course of three MSC injec-
tions. We found that multiple IV injections of allogeneic
MSCs are well tolerated in healthy horses. Allogeneic BM-
derived MSCs (BM-MSCs) may induce a mild immune re-
sponse that is characterized by an increased percentage of
CD8+ T cells in the peripheral blood.
Methods
Study design
This study was conducted in accordance with an ap-
proved institutional animal care and use committee
protocol. In total, 12 horses were enrolled in the study:
10 treatment and two controls. All horses were healthy
adults (5 to 14 years old, five females, seven geldings,
one quarter horse, 11 thoroughbreds) housed at the UC
Davis Center for Equine Health. Low-passage (P3-P5)
BM- and AT-derived MSCs from five and five horses, re-
spectively, were obtained from the UC Davis William R.
Pritchard Veterinary Medical Teaching Hospital (VMTH),
Regenerative Medicine Laboratory. These MSCs were ori-
ginally expanded for autologous patient treatment. Excess
cells not used for treatment were donated for research
purposes, with written owner consent. None of the MSC
donor horses was enrolled in the study. MSCs were cul-
tured and formulated for IV administration exactly as pre-
viously described [5,7]. Briefly, on the morning of the
treatment, MSCs were detached with 0.05% Trypsin-
EDTA solution (Gibco, Grand Island, NY, USA), neutral-
ized, and washed twice with phosphate buffer solution.
Each horse was injected with MSCs from the same allo-
geneic donor throughout the course of the study. Splenic
aspirates and peripheral blood were collected from four
additional healthy horses (5 to 14 years old, four females,
three thoroughbreds, one quarter horse) to obtain refer-
ence ranges for all analytes where ranges were not previ-
ously published. To minimize the number of animals
needed, all data from day 0 samples (collected prior to any
MSC administration) were included in the reference
ranges. All of the horses served as their own controls and
baseline data served as control for any statistical analysis.
We compared the data from the two control horses with
the baseline data to confirm that there was no sham injec-
tion/placebo effect.
Mesenchymal stem cell doses
AT- or BM-MSCs (25 × 106 per injection) were adminis-
tered on days 0, 14, and 28 (a total of 75 × 106 MSCs per
horse) in 3 mL of sterile saline (Baxter, Deerfield, IL,
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nute. This administration rate was selected on the basis
of previous experience in feline MSC transfusion at the
UC Davis VMTH. We have not observed any transfusion
reactions at this rate of cell delivery.
Clinical study and tissue collection
Temperature, pulse, and respiration data were recorded
prior to sedation. Horses were sedated with detomidine
hydrochloride (0.01 mg/kg; Pfizer Animal Health, Exton,
PA, USA)/butorphanol tartrate (0.01 mg/kg; Fort Dodge
Animal Health, Fort Dodge, IA, USA). Blood (60 mL)
was collected prior to each MSC injection (days 0, 14,
and 28) and on day 35 from all horses. Temperature,
pulse, and respiration rate were formally recorded prior
to MSC therapy, and horses were monitored throughout
the time of administration and for up to 2 hours after
administration (watching for respiratory stress and so
on). Horses were further checked daily to monitor any
adverse effects. Blood was submitted to the hematology
laboratory at the VMTH at UC Davis for blood cell
counts. Two control animals were injected with sterile
saline on the same time course to monitor the effects of
injection alone. Splenic aspiration (the dorsal and caudal
aspect of the splenic parenchyma was aspirated via ultra-
sound guidance, 5 to 10 mL) was performed on all
horses on days 0 and 35. Owing to problems associated
with poor cell yield and preparation for flow cytometry
analysis in day 0 samples, four additional healthy horses
were recruited for splenic sampling, as described in the
‘Study design’ section.
Serum cytokine analysis
Enzyme-linked immunosorbent assays for serum interleukin-
6 (IL-6) (diluted 1:25; R&D Systems, Minneapolis, MN,
USA), TGF-β1 (diluted 1:20, Human TGF-β1 Immuno-
assay; R&D Systems), and TNF-α (diluted 1:4, Equine
TNF-α Screening Set; Thermo Scientific, Waltham, MA,
USA) were performed exactly as previously described
[3,18]. Serum for IFN-γ and IL-17 determination was
submitted to the Animal Health Diagnostic Center, College
of Veterinary Medicine, Cornell University (Ithaca, NY,
USA).
Flow cytometry
Mononuclear cells were isolated from blood and spleen
by using gradient centrifugation (Ficoll; GE Healthcare,
Pittsburg, PA, USA) in accordance with previously de-
scribed protocols with the following modification [3]. Prior
to gradient centrifugation, splenic samples were passed
through a mesh strainer (Fisher Scientific, Pittsburgh, PA,
USA) and brought to a final volume of 35 mL with sterile
Dulbecco’s phosphate-buffered saline (DPBS) (Life Tech-
nologies, Frederick, MD, USA). For all labeling, a minimumof 105 cells were centrifuged and resuspended in 100 μL
of flow buffer: DPBS, 2% fetal bovine serum (Thermo
Fisher, Waltham, MA, USA), and 1 mM EDTA (Sigma-
Aldrich, St. Louis, MO, USA). The following antibodies
were used: mouse-anti-equine CD3 (clone UC F6G 1:250;
Jeffery Stott, University of California, Davis, CA, USA)
[19], mouse-anti-human CD21 (clone B-ly4 1:20; BD
Pharmingen, San Jose, CA, USA) [20,21], polyclonal
goat-anti-human CD25 (clone AF-223; R&D Systems)
[22], rat-anti-mouse/human FoxP3 (clone PCH101;
ebioscience, San Diego, CA, USA) [22], mouse-anti-CD4
(clone HB61A 1:133; VMRD, Pullman, WA, USA) [22],
mouse-anti-equine CD8 (clone F18P 1:500; J. Stott) [23],
and a donkey-anti-mouse secondary when necessary (1:50;
Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA, USA). All primary antibodies were incu-
bated for 30 minutes and all secondary antibodies were
incubated for 20 minutes in the dark. Cells were
washed with 2 mL of flow buffer and centrifuged after
each staining step and analyzed by flow cytometry as
previously described [24]. All samples were run on a
Cytomics FC500 flow cytometer (Beckman Coulter,
Indianapolis, IN, USA) and analyzed with FlowJo flow
cytometry software (Tree Star Inc., Ashland, OR, USA).
The percentage of CD25+ cells and the percentage of
FoxP3+ were gated from CD4+ cells.Statistical analysis
Data distribution was determined by using Shapiro-Wilk
normality tests. All data were analyzed by using non-
parametric analyses, and statistical significance was deter-
mined by using Kruskal-Wallis tests for bivariate data and
Dunn’s multiple comparison tests for time course (multi-
variate) data (GraphPad Prism 6.02; GraphPad Software,
Inc., La Jolla, CA, USA).Results
Intravenous injections of allogeneic adipose tissue- or
bone marrow-derived mesenchymal stem cells do not
induce a systemic inflammatory response
Baseline data were collected on all horses prior to and
after all MSC infusions. There were no significant
changes in temperature, heart rate, or respiration rate
as a result of MSC administration throughout the
course of the study (Figure 1A). There were no signifi-
cant changes in the absolute number of blood leuko-
cytes, neutrophils, or lymphocytes over the course of
the study (Figure 1B-D). There were also no significant
changes in the serum concentration of IL-6, IFN-γ, IL-
17, TGF-β, or TNF-α, further demonstrating that the
MSCs did not elicit a systemic inflammatory response
(Figure 2).
Figure 1 Multiple allogeneic mesenchymal stem cell (MSC) injections do not induce anaphylaxis or alter leukocyte concentration. (A) There were
no significant changes in temperature, heart rate, or respiration rate throughout the course of MSC administration. (B) White blood cell count
(WBC) did not change throughout the course of the study. Neutrophil (C) and lymphocyte (D) counts did not change throughout the course of
the study. These data demonstrate that multiple high-dose injections of allogeneic MSCs do not result in an anaphylactic response and do not
elicit a change in leukocyte concentration. Data are presented as mean ± standard error of the mean. Grey boxes demonstrate the 95%
confidence interval (CI) of the day 0 and control samples. AT, adipose tissue; BM, bone marrow; D, day.
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mesenchymal stem cell increase blood CD8+ T cells
We measured the percentage of circulating T- and B-cell
numbers to determine whether multiple MSC injections
altered circulating lymphocyte phenotype. The percentage
of CD21+ B cells and CD4+ T cells did not change signifi-
cantly in any of the experimental groups (Figure 3A, B).
However, the percentage of CD8+ T cells was significantly
increased on days 28 and 35 (12.5% ± 1.1% and 11.8% ±
1.4%, respectively) in horses injected with BM-MSCs com-
pared with control horses (4.8% ± 0.7%). In contrast, the
percentage of CD8+ T cells was not significantly elevated
in horses that received AT-MSCs (Figure 3C). The
changes in CD8+ T cells significantly decreased the CD4/
CD8 T-cell ratio in horses that received BM-MSCs (6.73%
± 0.73% on day 28 and 7.45% ± 1.17% on day 35) com-
pared with control horses (20.64% ± 4.82%, Figure 3D).
These data demonstrate that repeated injections of BM-
MSC elicit a greater CD8+ T-cell response when com-
pared with controls but that AT-MSCs do not.
Allogeneic intravenous injection of bone marrow-derived
mesenchymal stem cells may increase splenic FoxP3
regulatory T cells
Splenic lymphocyte subsets were evaluated one week
after the final MSC injection in all horses. Three IV in-
jections of allogeneic AT- or BM-MSCs did not change
the percentage of splenic CD21+ B cells, CD4+ T cells,
or CD8+ T cells (Figure 4A-C). Unlike the percentage ofCD8+ T cells and the CD4/CD8 ratio in blood, the
splenic lymphocyte CD4/CD8 ratio did not change after
MSC injections (Figure 4D). These data demonstrate
that whereas circulating numbers of CD8+ T cells are in-
creased after repeated BM-MSC injections, splenic CD8+
T cells do not reflect or mimic this response to allogen-
eic MSCs regardless of the MSC source.
There were no significant changes in circulating FoxP3+
Treg cell numbers (data not shown). Interestingly, the
number of splenic FoxP3+ Treg cells was significantly
greater in horses that received BM-MSCs (2% ± 0.7%)
compared with horses that received AT-MSCs (0.4% ±
0.1%) but not compared with control horses (0.9% ± 0.4%).
(Figure 4E, F). These data show that whereas overall CD4+
T-cell numbers did not change as a result of MSC injec-
tion, Treg cell numbers may be influenced by MSC
source.
Discussion
Overall, the data demonstrate that multiple IV injections
of allogeneic MSCs are well tolerated in horses. We
administered three dosages of 25 × 106 allogeneic MSCs
derived from either AT or BM (a total of 75 × 106 MSCs
each), with two weeks between each injection. There
were no measurable adverse clinical responses to infu-
sion. We did observe increased circulating CD8+ T-cell
numbers that suppressed the CD4/CD8 ratio in horses
that received BM-MSCs. We also observed an elevated
splenic FoxP3+ Treg cell population in horses that
Figure 2 Multiple allogeneic mesenchymal stem cell (MSC) injections do not induce a systemic cytokine response. Serum concentration of
pro-inflammatory cytokines (A) interleukin-6 (IL-6), (B) interferon-gamma (IFN-γ), and (C) tissue necrosis factor-alpha (TNF-α) did not change
significantly as a result of multiple MSC injections. Neither (D) IL-17 nor (E) transforming growth factor-beta (TGF-β) was modulated by MSC
administration. These data demonstrate that multiple high-dose injections of allogeneic MSCs do not result in a systemic inflammatory response.
Data are presented as mean ± standard error of the mean. Grey boxes demonstrate the 95% confidence interval (CI) of the day 0 and control
samples. AT, adipose tissue; BM, bone marrow; D, day.
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AT-MSCs, but not compared with control. Although re-
peated IV injection of allogeneic MSCs from either AT
or BM appears to be well tolerated in healthy horses,
BM-MSCs might elicit an elevated CD8+ T-cell response
and may also promote the development of Treg cells.
Although no clinical signs were associated with these
immune cell alterations, the underlying mechanism of
these immune reactions and their potential longer-term
clinical outcome should be addressed in future studies.
IV injection of MSCs is commonly used successfully in
both human [25] and veterinary [1,26] clinical applica-
tions but is underutilized in equine medicine. Though
not yet well studied in equine medicine, the IV injection
route, in human patients, is highly advantageous for
treatment of systemic inflammatory, infectious, or ische-
mic diseases in which local lesion injection is notfeasible. MSCs are typically found in the lungs, gut, kid-
ney, liver, thymus, and skin following IV transplantation
in non-injury models and are further found at the site of
injury in injured animal models [27]. A potential advan-
tage of IV injection is that it may result in higher sur-
vival rates of MSCs following transplantation [28].
Additionally, systemic administration does not have the
same injection volume limitations that can hinder local
administration. As such, systemic IV MSC administra-
tion could potentially support larger cell doses than local
administration.
Injections of 20 × 106 MSCs have been previously ad-
ministered to horses through local injection routes and
are well tolerated [4]. More recently, a single IV injec-
tion of 0.2 to 1 × 106 MSCs of allogeneic MSCs was
shown to be well tolerated in clinically healthy horses.
We chose a higher dose of MSCs for this study as the
Figure 3 Multiple allogeneic mesenchymal stem cell (MSC) injections increase CD8+ T-cell numbers. There were no significant changes in the
percentages of circulating CD21+ B cells (A) or CD4+ T cells (B) following multiple injections of MSCs. However, CD8+ T-cell percentages increased
significantly in horses injected with bone marrow (BM)-derived MSCs (12.46% at day 28 and 11.76% at day 35) compared with control (C). The
increase in CD8+ T cells decreased the CD4/CD8 ratio significantly (D). Data are presented as mean ± standard error of the mean. Grey boxes
demonstrate the 95% confidence interval (CI) of the day 0 and control samples. *P <0.05. AT, adipose tissue; D, day.
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the horse had not yet been documented. In human
medicine, IV injection of 1 to 2 × 106 MSCs per kilogram
is a common dose for immunomodulatory applications
of MSCs [25]. A comparative dose would be on the
order of 108 to 109 MSCs in horses. We found that three
serial injections of 25 × 106 MSCs were well tolerated in
healthy horses. However, a potential limitation of this
study, based on published trials in human patients, is
that a total of 75 × 106 MSCs may not be therapeutically
effective in horses for systemic treatment of immune-
mediated diseases and disorders. If 108 to 109 cells are
truly deemed necessary for efficacy in the treatment of
equine systemic inflammatory diseases, cell bioreactors
would be needed to generate these cell numbers.
There were no adverse reactions to AT-MSCs follow-
ing IV injection. However, we did find increased CD8+
T-cell numbers following repeated injection of BM-
MSCs in healthy horses. These data suggest that re-
peated BM-MSC injection may elicit a mild cytotoxic re-
sponse to allogeneic antigens, which is consistent with
findings in other healthy animal models [29]. Our la-
boratory has previously investigated the differences in
the immunomodulatory properties of equine MSCs that
are derived from different tissue sources, including AT
and BM [3,15]. AT- and BM-MSCs were similar in their
capacity to inhibit mitogen-induced T-cell proliferation
and T-cell secretion of IFN-γ and TNF-α in vitro andwere similar in their capacity to secrete the immuno-
modulatory mediators PGE2, TGF-β, and IL-6. However,
BM-MSCs showed nitric oxide activity whereas AT-
MSC did not [3]. Furthermore, the mechanism by which
these MSCs decrease lymphocyte numbers in vitro also
differs. AT-MSCs induced T-cell apoptosis in activated T
cells, whereas BM-MSCs induced cell cycle arrest in
similar conditions [15]. Nevertheless, none of these
in vitro characteristics provides an explanation for the
differences in CD8 T-cell numbers noted in the present
study. It may be the low number of animals enrolled
with unknown tissue matching. An additional consider-
ation is that BM-MSCs are more heterogeneous, which
may support CD8 T-cell activation at early passage,
whereas AT-MSCs are more homogenous. Moreover, we
have found that 37% of horses that received allogeneic
MSC therapy (systemically and locally) developed MSC-
specific antibody response (Sean Owens, in review).
However, MSCs have also been shown to reduce immune
response to allo-antigens in other species [17]. Import-
antly, allogeneic MSCs are being explored in human and
veterinary clinical trials because they are readily available
and they do not elicit acute or delayed immune-mediated
hypersensitivity [1,10]. Finally, this study was limited to
non-injury model animals. Previous studies have shown
that MSC injection in non-injury model horses may elicit
an inflammatory response [3,30]. Future applications of
intravenously injected BM-MSCs should monitor for a
Figure 4 Multiple allogeneic mesenchymal stem cell (MSC) injections result in changes in splenic regulatory T cell percentages. (A-D) There were
no significant changes in splenic CD21+ B-cell (A), CD4+ T-cell (B), or CD8+ T-cell percentages (C) or CD4/CD8 ratios (D) following multiple MSC
injections. (E) There were no significant changes in activated (CD25+) lymphocyte proportions. (F) There were significantly higher percentages of
splenic FoxP3+ regulatory T cells in the horses injected with bone marrow (BM)-derived MSCs compared with horses injected with adipose tissue
(AT)-derived MSCs. Data are presented as mean ± standard error of the mean. *P <0.05.
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was a function of the non-injured model or a more con-
sistent problem with repeated IV injection of allogeneic
BM-MSCs in horses.
In human in vitro assays, MSCs inhibit T helper 17
(Th17) differentiation and activation and induce a Treg
phenotype [31]. A previous study in horses has charac-
terized phenotypic and functional properties of Treg
cells [22]. Our findings in horses show that different
MSC sources may uniquely impact splenic Treg cell
numbers. Findings from our lab [15] and others [4,32]
confirm that MSCs from different tissue sources vary intheir functions. However, sampling limitations and the
relatively non-uniform distribution of the cells that com-
prise the spleen hindered our ability to thoroughly investi-
gate the ability of either MSC source to generate splenic
Treg cells. Further testing in a disease model with a larger
sample size is needed to demonstrate therapeutic efficacy
of one MSC source over another and the impact that
MSC source may have on Treg production in vivo.
Conclusions
The results of this study demonstrate that repeated IV
allogeneic MSC injections in horses are well tolerated.
Kol et al. Stem Cell Research & Therapy  (2015) 6:73 Page 8 of 9In light of the safety profile that was demonstrated in
this study, further development of novel MSC therapies
for equine orthopedic and immune-mediated diseases
may be pursued.
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